Exelixis ((EXEL)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Exelixis is conducting a Phase 3 clinical trial titled A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma. The study aims to evaluate the efficacy of XL092 combined with nivolumab compared to sunitinib in patients with advanced or metastatic non-clear cell renal cell carcinoma (nccRCC) who have not received prior systemic anticancer therapy. This study is significant as it explores potential new treatment options for a challenging cancer type.
Intervention/Treatment: The trial tests two interventions: an experimental combination of XL092 and nivolumab, and sunitinib as an active comparator. XL092 and nivolumab are drugs intended to target and inhibit cancer cell growth, while sunitinib is a standard treatment used for comparison.
Study Design: This is a randomized, open-label, controlled study with a parallel intervention model. Participants are randomly assigned to either the experimental group or the active comparator group. The primary purpose of the trial is treatment, with no masking involved, meaning both researchers and participants know which treatment is being administered.
Study Timeline: The study began on January 1, 2023. The primary completion and estimated completion dates are not specified, but the last update was submitted on July 11, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might be available.
Market Implications: This study update could influence Exelixis’ stock performance and investor sentiment, as positive results may enhance the company’s market position in the oncology sector. Investors should also consider the competitive landscape, as other companies are developing similar treatments for renal cell carcinoma.
The study is ongoing, with further details available on the ClinicalTrials portal.